Study of Istradefylline (KW-6002) for the Treatment of Restless Legs Syndrome

Completed · Phase 2

Conditions studied: Sleep Disorder, Restless Legs Syndrome

In brief

The primary purpose of this study is to evaluate the efficacy, safety, and tolerability of 40 mg per day of istradefylline (KW6002) in patients with Restless Legs Syndrome.

Key facts

Study ID

NCT00199446

Run by

Kyowa Kirin, Inc.

People needed

160

Starts

2005-07-01

Expected to finish

2006-10-01

Last updated by the study team

2024-04-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• RLS that is mild to moderate in severity, non-nursing and non-pregnant if female, with an otherwise normal examination.

You may not qualify if…

• Unable to stop other RLS medication, treatment with excluded medications, abnormal medical status.

Where it is running

• Kyowa Pharmaceutical Inc. — Princeton, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.